
As the clock strikes mid-December, AVAX graces us with its presence at a modest $13, a far cry from its former glory but steadfastly above a demand zone that has proven more resilient than a Wildean wit. This zone, my friends, has absorbed sell pressure with the grace of a Victorian lady fainting at a ball, repeatedly acting as a structural floor across multiple timeframes. The price, ever the drama queen, has spent weeks consolidating, refusing to accelerate lower, much to the chagrin of the bears. 🐻